Renal Business Today

AMAG Pharmaceuticals

Canada Approves Feraheme to Treat CKD Patients

LEXINGTON, Mass.—Health Canada, on Dec. 8 granted marketing approval to AMAG Pharmaceuticals and Takeda Canada for the iron drug Feraheme. ...More
December 12, 2011
Posted in News, Business, Clinical & Pharma, Government & Regulation
AMAG Hires Financial Advisor; Tries to Enhance Stockholder Value

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it has hired Jefferies & Company, Inc. as a strategic advisor. ...More
November 17, 2011
Posted in News, Business
AMAG Board Opposes MSMB Capital Acquisition Offer

LEXINGTON, Mass.—AMAG Pharmaceuticals’ board of directors has unanimously opposed MSMB Capital's $381 million takeover offer for the Feraheme manufacturer. ...More
August 8, 2011
Posted in News, Business
Amag Pharmaceuticals Receives Acquisition Offer

Amag Pharmaceuticals, Inc., a company that makes Feraheme, a treatment for iron deficiency anemia in adults with chronic kidney disease, this week received an unsolicited buyout offer. ...More
August 5, 2011
Posted in News, Clinical & Pharma
AMAG Names New Chief Financial Officer

LEXINGTON, Mass.—AMAG Pharmaceuticals has named Frank E. Thomas to the position of Executive Vice President and Chief Financial Officer. ...More
August 1, 2011
Posted in News, Business
AMAG Updates Feraheme Label

LEXINGTON, Mass.—AMAG Pharmaceuticals announced June 21 that it has updated the product label for Feraheme (ferumoxytol) Injection for Intravenous (IV) use. ...More
June 21, 2011
Posted in News, Clinical & Pharma, Government & Regulation
FDA Approves CMOs to Manufacture Feraheme

LEXINGTON, Mass.—The U.S. Food and Drug Administration (FDA) has approved two second source contract manufacturing organizations (CMO) to manufacture AMAG Pharmaceutical’s Feraheme® (ferumoxytol) Injection for Intravenous (IV) use. ...More
May 26, 2011
Posted in News, Business, Government & Regulation
AMAG Increases Revenues, Narrows Losses in 2010

LEXINGTON, Mass.—AMAG Pharmaceuticals increased its revenues in 2010 while also reducing its losses, according to the company, which manufactures the iron drug Feraheme. ...More
March 1, 2011
Posted in News, Business
AMAG Updates Feraheme Label

LEXINGTON, Mass.—AMAG Pharmaceuticals said Nov. 29 that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding an update to the product label for Feraheme Injection for intravenous (IV) use. ...More
November 29, 2010
Posted in News, Business, Clinical & Pharma, Government & Regulation
AMAG Reports Safety Issues with Feraheme, Cuts Workforce

AMAG Pharmaceuticals has reported potential safety issues with its iron management drug Feraheme and has decided to cut 24 percent of its workforce in an effort to restructure the company, the company announced in a news release. ...More
November 1, 2010
Posted in Blog, Clinical & Pharma, Government & Regulation